Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient.

Jorgensen SCJ, McDonald P, Mynatt RP, Pogue JM, Lerner SA, Dhar S, Salimnia H, Rybak MJ.

J Antimicrob Chemother. 2018 Dec 1;73(12):3529-3531. doi: 10.1093/jac/dky346. No abstract available.

PMID:
30188993
2.

A novel approach in the management of right-sided endocarditis: percutaneous vegectomy using the AngioVac cannula.

Thiagaraj AK, Malviya M, Htun WW, Telila T, Lerner SA, Elder MD, Schreiber TL.

Future Cardiol. 2017 May;13(3):211-217. doi: 10.2217/fca-2016-0076. Epub 2017 Mar 22.

PMID:
28326804
3.
4.

Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI.

Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Review.

5.

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ.

Blood. 2009 Jul 30;114(5):957-64. doi: 10.1182/blood-2009-03-210591. Epub 2009 May 4.

6.

Ray and van cittert-zernike characterization of spatial coherence.

Sasián JM, Lerner SA, Lin TY, Laughlin L.

Appl Opt. 2001 Mar 1;40(7):1037-43.

PMID:
18357087
7.

Multilayer-coating-induced aberrations in extreme-ultraviolet lithography optics.

Liang C, Descour MR, Sasian JM, Lerner SA.

Appl Opt. 2001 Jan 1;40(1):129-35.

PMID:
18356983
8.

Optical design with parametrically defined aspheric surfaces.

Lerner SA, Sasian JM.

Appl Opt. 2000 Oct 1;39(28):5205-13.

PMID:
18354517
9.

Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).

Juretschko S, Labombardi VJ, Lerner SA, Schreckenberger PC; Pseudomonas AST Study Group.

J Clin Microbiol. 2007 Apr;45(4):1339-42. Epub 2007 Jan 17.

10.

Improvements in antimicrobial prescribing for treatment of upper respiratory tract infections through provider education.

Juzych NS, Banerjee M, Essenmacher L, Lerner SA.

J Gen Intern Med. 2005 Oct;20(10):901-5.

11.

Multiplex PCR for detection of aminoglycoside resistance genes in enterococci.

Vakulenko SB, Donabedian SM, Voskresenskiy AM, Zervos MJ, Lerner SA, Chow JW.

Antimicrob Agents Chemother. 2003 Apr;47(4):1423-6.

12.

Mutations in the aph(2")-Ic gene are responsible for increased levels of aminoglycoside resistance.

Lee HK, Vakulenko SB, Clewell DB, Lerner SA, Chow JW.

Antimicrob Agents Chemother. 2002 Oct;46(10):3253-6.

13.

Rare presentation of Streptococcus pneumoniae pneumonia with bacteremia and multiple subcutaneous abscesses.

Shahin GS, Lerner SA.

Eur J Clin Microbiol Infect Dis. 2002 Aug;21(8):611-2. Epub 2002 Aug 21. Review.

PMID:
12226693
14.

Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

Vakulenko SB, Golemi D, Geryk B, Suvorov M, Knox JR, Mobashery S, Lerner SA.

Antimicrob Agents Chemother. 2002 Jun;46(6):1966-70.

15.

Aminoglycoside ototoxicity: a human temporal bone study.

Hinojosa R, Nelson EG, Lerner SA, Redleaf MI, Schramm DR.

Laryngoscope. 2001 Oct;111(10):1797-805.

PMID:
11801948
16.

Conjoint molecules of cephalosporins and aminoglycosides.

Grapsas I, Lerner SA, Mobashery S.

Arch Pharm (Weinheim). 2001 Sep;334(8-9):295-301.

PMID:
11688141
17.

Aminoglycoside resistance genes aph(2")-Ib and aac(6')-Im detected together in strains of both Escherichia coli and Enterococcus faecium.

Chow JW, Kak V, You I, Kao SJ, Petrin J, Clewell DB, Lerner SA, Miller GH, Shaw KJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2691-4.

18.

High-level amikacin resistance in Pseudomonas aeruginosa associated with a 3'-phosphotransferase with high affinity for amikacin.

Torres C, Perlin MH, Baquero F, Lerner DL, Lerner SA.

Int J Antimicrob Agents. 2000 Aug;15(4):257-63.

PMID:
10929874
19.

Clinical impact of antibiotic resistance.

Lerner SA.

Adv Exp Med Biol. 1998;456:7-15. Review. No abstract available.

PMID:
10549361
20.

Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from Escherichia coli.

Vakulenko SB, Taibi-Tronche P, Tóth M, Massova I, Lerner SA, Mobashery S.

J Biol Chem. 1999 Aug 13;274(33):23052-60.

21.

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL.

Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55.

22.

Community-acquired pneumonia.

Brown PD, Lerner SA.

Lancet. 1998 Oct 17;352(9136):1295-302. Review.

PMID:
9788476
23.

Empirical therapy for community-acquired pneumonia.

Brown PD, Lerner SA.

Ann Intern Med. 1998 Sep 15;129(6):510. No abstract available.

PMID:
9735098
24.

Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.

Vakulenko SB, Geryk B, Kotra LP, Mobashery S, Lerner SA.

Antimicrob Agents Chemother. 1998 Jul;42(7):1542-8.

25.

Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.

Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, Manavathu EK, Lerner SA.

Antimicrob Agents Chemother. 1998 May;42(5):1295-7.

26.

Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS.

Slavik RS, Rybak MJ, Lerner SA.

Ann Pharmacother. 1998 Feb;32(2):189-92.

PMID:
9496403
27.

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Alangaden GJ, Lerner SA.

Clin Infect Dis. 1997 Nov;25(5):1213-21. Review.

PMID:
9402384
28.

A novel gentamicin resistance gene in Enterococcus.

Chow JW, Zervos MJ, Lerner SA, Thal LA, Donabedian SM, Jaworski DD, Tsai S, Shaw KJ, Clewell DB.

Antimicrob Agents Chemother. 1997 Mar;41(3):511-4.

29.

Case/control study of the role of splenectomy in chronic lymphocytic leukemia.

Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ.

J Clin Oncol. 1997 Jan;15(1):52-60.

PMID:
8996124
30.
31.

Isolation and characterization of a species-specific DNA probe for the detection of Candida krusei.

Manavathu EK, Vakulenko SB, Obedeanu N, Lerner SA.

Curr Microbiol. 1996 Sep;33(3):147-51.

PMID:
8672089
32.

Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams.

Vakulenko SB, Tóth M, Taibi P, Mobashery S, Lerner SA.

Antimicrob Agents Chemother. 1995 Aug;39(8):1878-80.

33.

Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.

Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA.

Antimicrob Agents Chemother. 1995 Aug;39(8):1700-3.

35.
36.

Critical hydrogen bonding by serine 235 for cephalosporinase activity of TEM-1 beta-lactamase.

Imtiaz U, Manavathu EK, Lerner SA, Mobashery S.

Antimicrob Agents Chemother. 1993 Nov;37(11):2438-42.

37.

Elucidation of the role of arginine-244 in the turnover processes of class A beta-lactamases.

Zafaralla G, Manavathu EK, Lerner SA, Mobashery S.

Biochemistry. 1992 Apr 21;31(15):3847-52.

PMID:
1567841
38.
39.

Isolation and characterization of a species-specific DNA probe for Candida albicans.

Oren I, Manavathu EK, Lerner SA.

Nucleic Acids Res. 1991 Dec;19(25):7113-6.

40.

Single daily dose therapy with aminoglycosides.

Nordström L, Lerner SA.

J Hosp Infect. 1991 Jun;18 Suppl A:117-29. Review.

PMID:
1679774
41.

Bone-fill in guided tissue regeneration of periodontal defects.

Lerner SA.

Compendium. 1991 Apr;12(4):248, 250, 252 passim.

PMID:
1893389
42.

Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.

Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, Thompson GA, Kenny MT, Yuh L.

Antimicrob Agents Chemother. 1991 Apr;35(4):696-700.

43.

Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

Kaatz GW, Seo SM, Dorman NJ, Lerner SA.

J Infect Dis. 1990 Jul;162(1):103-8.

PMID:
2141343
44.
45.
46.

Monitoring beta-lactamase activity in vivo by 13C nuclear magnetic resonance spectroscopy.

Mobashery S, Lerner SA, Johnston M.

Antimicrob Agents Chemother. 1988 Aug;32(8):1196-203.

47.

Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms.

Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA.

Rev Infect Dis. 1988 Jul-Aug;10(4):892-8. Review.

PMID:
3142013
48.

Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding proteins.

Quinn JP, DiVincenzo CA, Lucks DA, Luskin RL, Shatzer KL, Lerner SA.

J Infect Dis. 1988 Apr;157(4):764-9.

PMID:
3346567
49.
50.

Optimal duration of treatment of urinary tract infections.

Lerner SA.

Eur Urol. 1987;13 Suppl 1:26-31.

PMID:
3569375

Supplemental Content

Loading ...
Support Center